SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc. (SGMT) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Profitability (D). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.6) | D (1.4) | B- (3.1) | A+ (5.0) | C+ (2.7) |
| 2026-11-07 | C+ (2.5) | D+ (1.5) | D (1.4) | B (3.3) | A+ (5.0) | C+ (2.7) |
| 2026-10-31 | C+ (2.5) | D (1.5) | D (1.4) | B+ (3.8) | A+ (5.0) | C+ (2.8) |
| 2026-10-24 | C+ (2.5) | D (1.5) | D (1.4) | A- (3.9) | A+ (5.0) | B- (2.9) |
| 2026-10-17 | C+ (2.5) | D (1.5) | D (1.4) | A- (4.0) | A+ (5.0) | B- (2.9) |